Fertility-Preserving Treatment in Young Women With Grade 1 Presumed Stage IA Endometrial Adenocarcinoma: A Meta-Analysis
- PMID: 29266019
- DOI: 10.1097/IGC.0000000000001164
Fertility-Preserving Treatment in Young Women With Grade 1 Presumed Stage IA Endometrial Adenocarcinoma: A Meta-Analysis
Abstract
Objectives: The aim of this study was to investigate the different efficacies of various fertility-preserving therapies for grade 1 presumed stage IA endometrial cancer.
Methods: We searched the major online databases (PubMed, MEDLINE, Cochrane Library, Web of Science, and Ovid) and retrieved all the research on fertility-preserving treatment for young, grade 1 presumed stage IA endometrial adenocarcinoma patients since January 2000. We used the systemic evaluation of the Cochrane Collaboration to select the literature and merge the data we collected using R3.2.2 software (R Development Core Team, Auckland, New Zealand). By comparing the remission, recurrence, and pregnancy rates, we evaluated the efficiency of 3 existing fertility-preserving treatments indirectly: a) taking oral progestin only therapy, b) hysteroscopic resection followed by progestin therapy, and c) intrauterine progestin therapy: levonorgestrel-releasing intrauterine system combined with gonadotropin-releasing hormone agonist/progestin therapy.
Results: Twenty-eight studies met the selection criteria. A total of 619 cases were included in this study. The group that took oral progestin only (456 patients) achieved a complete remission rate (CRR), recurrence rate (ReR), and pregnancy rate (PregR) of 76.3%, (95% confidence interval [CI], 70.7%-81.1%); 30.7% (95% CI, 21.0%-42.4%); and 52.1% (95% CI, 41.2%-66.0%), respectively. The hysteroscopic resection followed by progestin therapy group (73 patients) achieved a CRR, ReR, and PregR of 95.3% (95% CI, 87.8%-100%); 14.1% (95% CI, 7.1%-26.1%); and 47.8% (95% CI, 33.0%-69.5%), respectively. The intrauterine progestin therapy group (90 patients) achieved a CRR, ReR, and PregR of 72.9% (95% CI, 60.4%-82.5%); 11.0% (95% CI, 5.1%-22.0%); and 56.0% (95% CI, 37.3%-73.1%), respectively.
Conclusions: The existing results show that patients who received hysteroscopic resection followed by progestin therapy achieved the highest CRR. Patients who received oral progestin only might be more likely to recur and have more systemic adverse effects. Recent intrauterine progestin therapy such as levonorgestrel-releasing intrauterine system combined with gonadotropin-release hormone receptor agonist/progestin have a satisfactory PregR and low ReR rate. Considering the inherent limitations of the studies we included, further well-designed, randomized controlled trials are necessary to confirm and update this analysis.
Similar articles
-
Fertility Preserving Treatment With Hysteroscopic Resection Followed by Progestin Therapy in Young Women With Early Endometrial CancerF Falcone et al. J Gynecol Oncol 28 (1), e2. PMID 27670256.The addition of a standardized three-step resectoscopy to progestin would seem to improve the efficacy of progestin alone. High pregnancy and live birth rates were observ …
-
Fertility-preserving Treatment of Stage IA, Well-Differentiated Endometrial Carcinoma in Young Women With Hysteroscopic Resection and High-Dose Progesterone TherapyHC Yang et al. Taiwan J Obstet Gynecol 58 (1), 90-93. PMID 30638488.Hysteroscopic tumor resection followed by progestin therapy for early-stage and well-differentiated endometrial cancer is a safe conservative treatment strategy. It could …
-
Fertility-Sparing Treatment of Early Endometrial Cancer and Complex Atypical Hyperplasia in Young Women of Childbearing PotentialSM Pronin et al. Int J Gynecol Cancer 25 (6), 1010-4. PMID 25950126.The suggested conservative treatment strategy can be considered as a valid therapeutic option for young women of childbearing potential with atypical endometrial hyperpla …
-
Efficacy of Oral or Intrauterine Device-Delivered Progestin in Patients With Complex Endometrial Hyperplasia With Atypia or Early Endometrial Adenocarcinoma: A Meta-Analysis and Systematic Review of the LiteratureJ Baker et al. Gynecol Oncol 125 (1), 263-70. PMID 22196499. - ReviewThere is a lack of high quality evidence for the efficacy of progestin in CAH or EC. The available evidence however suggests that treatment with oral or intrauterine prog …
-
Oncologic and Reproductive Outcomes With Progestin Therapy in Women With Endometrial Hyperplasia and Grade 1 Adenocarcinoma: A Systematic ReviewCC Gunderson et al. Gynecol Oncol 125 (2), 477-82. PMID 22245711. - ReviewBased on this systematic review of the contemporary literature, endometrial hyperplasia has a significantly higher likelihood of response (66%) to hormonal therapy than g …
Cited by 3 PubMed Central articles
-
Weight Control Is Vital for Patients With Early-Stage Endometrial Cancer or Complex Atypical Hyperplasia Who Have Received Progestin Therapy to Spare Fertility: A Systematic Review and Meta-AnalysisM Li et al. Cancer Manag Res 11, 4005-4021. PMID 31190979.Objectives: This study aimed to identify potential prognostic factors for patients with complex atypical hyperplasia (CAH) or early-stage endometrial cancer (EC) w …
-
Fertility Sparing Treatment in Patients With Early Stage Endometrial Cancer, Using a Combination of Surgery and GnRH Agonist: A Monocentric Retrospective Study and Review of the LiteratureS Tock et al. Front Med (Lausanne) 5, 240. PMID 30211167.All patients received GnRH agonist for 3 months after an endometrial resection combined with a laparoscopy to exclude concomitant ovarian tumor and/or other extra-uterine …
-
MIG-6 Suppresses Endometrial Epithelial Cell Proliferation by Inhibiting phospho-AKTJY Yoo et al. BMC Cancer 18 (1), 605. PMID 29843645.These data suggest that endometrial epithelial cell proliferation is regulated by P4 mediated Mig-6 inhibition of AKT phosphorylation, uncovering new mechanisms of P4 act …
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous